Loading...
XNAS
SNGX
Market cap4mUSD
Jul 25, Last price  
1.32USD
1D
-5.04%
1Q
-39.17%
Jan 2017
-41.33%
Name

Soligenix Inc

Chart & Performance

D1W1MN
P/E
P/S
36.10
EPS
Div Yield, %
Shrs. gr., 5y
83.08%
Rev. gr., 5y
-51.89%
Revenues
119k
-85.78%
3,075,7362,313,0201,258,0172,310,2652,816,0371,947,6287,662,8223,144,6203,224,1527,043,0168,768,39010,448,7945,432,4725,241,4484,629,9162,359,447824,268948,911839,359119,371
Net income
-9m
L+41.28%
-4,720,260-8,163,346-6,164,643-3,422,027-6,034,453-7,386,579-2,378,594-4,163,007-10,058,996-6,706,972-7,831,230-3,245,383-7,147,083-8,899,975-9,355,592-17,688,522-12,550,973-13,798,339-6,140,730-8,675,690
CFO
-8m
L-2.33%
-4,670,702-4,141,830-5,997,833-2,788,372-4,603,189-5,730,582-1,951,738-2,635,533-4,456,973-2,466,729-5,386,308-4,982,421-6,510,567-7,244,631-7,509,567-11,454,426-11,739,620-12,649,021-8,604,109-8,403,618
Earnings
Aug 07, 2025

Profile

Soligenix, Inc., a late-stage biopharmaceutical company, focuses on developing and commercializing products to treat rare diseases in the United States. It operates in two segments, Specialized BioTherapeutics and Public Health Solutions. The Specialized BioTherapeutics segment develops SGX301 (HyBryte), a novel photodynamic therapy, which has completed Phase III clinical trial for the treatment of treat cutaneous T-cell lymphoma; and SGX942, an innate defense regulator technology that is in Phase III clinical trial for the treatment of inflammatory diseases, including oral mucositis in head and neck cancer. This segment also offers proprietary formulations of oral beclomethasone 17,21-dipropionate for the prevention/treatment of gastrointestinal disorders characterized by severe inflammation, including SGX203 for pediatric Crohn's disease; and SGX302 that is in Phase I/II clinical trial for the treatment of mild-to-moderate psoriasis. The Public Health Solutions segment is involved in the development of RiVax, a ricin toxin vaccine candidate, which has completed Phase Ia and Ib clinical trials; SGX943, a therapeutic candidate that is in pre-clinical stage for the treatment of antibiotic resistant and emerging infectious diseases; ThermoVax, a technology in pre-clinical development for thermostabilizing vaccines; and CiVax, a vaccine candidate in pre-clinical development for the prevention of COVID-19. The company was formerly known as DOR BioPharma, Inc. and changed its name to Soligenix, Inc. in 2009. Soligenix, Inc. was incorporated in 1987 and is headquartered in Princeton, New Jersey.
IPO date
Apr 04, 1994
Employees
13
Domiciled in
US
Incorporated in
US

Valuation

Title
USD in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFYFY
2024‑122023‑122022‑122021‑122020‑122019‑122018‑122017‑122016‑122015‑12
Income
Revenues
119
-85.78%
839
-11.55%
949
15.12%
Cost of revenue
9,559
8,537
15,188
Unusual Expense (Income)
NOPBT
(9,439)
(7,698)
(14,239)
NOPBT Margin
Operating Taxes
(1,768)
(1,155)
Tax Rate
NOPAT
(9,439)
(5,930)
(13,084)
Net income
(8,676)
41.28%
(6,141)
-55.50%
(13,798)
9.94%
Dividends
Dividend yield
Proceeds from repurchase of equity
5,813
11,587
79
BB yield
-129.90%
-3,156.02%
-97.83%
Debt
Debt current
1,485
2,494
10,007
Long-term debt
112
1,356
576
Deferred revenue
Other long-term liabilities
43
Net debt
(6,223)
(4,596)
(2,801)
Cash flow
Cash from operating activities
(8,404)
(8,604)
(12,649)
CAPEX
(1)
(13)
Cash from investing activities
(13)
Cash from financing activities
7,762
3,664
77
FCF
(9,307)
(5,812)
(13,315)
Balance
Cash
7,820
8,446
13,360
Long term investments
24
Excess cash
7,814
8,404
13,336
Stockholders' equity
(233,922)
(225,672)
(219,536)
Invested Capital
239,525
231,810
227,305
ROIC
ROCE
EV
Common stock shares outstanding
1,660
485
179
Price
2.70
255.92%
0.76
67.52%
0.45
-31.55%
Market cap
4,475
1,118.80%
367
352.62%
81
-26.54%
EV
(1,748)
(4,229)
(2,720)
EBITDA
(9,434)
(7,691)
(14,214)
EV/EBITDA
0.19
0.55
0.19
Interest
214
49
823
Interest/NOPBT